Ligand Pharmaceuticals Hits New 52-Week High of $275.98

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 275.98 on June 18, 2026. This achievement underscores the company's robust performance in the pharmaceuticals and biotechnology sector, where it has demonstrated a remarkable one-year performance of 245.63%, significantly outpacing the S&P 500's 25.41% return. With a market capitalization of USD 3,898 million, Ligand Pharmaceuticals is classified as a small-cap company. The firm boasts a price-to-earnings (P/E) ratio of 68.00, reflecting its growth potential. Notably, the company is net-debt free, which positions it favorably in terms of financial stability. In recent quarters, Ligand has reported positive results, including an operating cash flow of USD 123.57 million and a net profit of USD 36.68 million, which has grown by 157.25%. The company's return on equity stands at 5.61%, and it maintains a price-to-book ratio of 3.83, indicating an attractive valuation. With 100% institutional holdings, Ligand Pharmaceuticals continues to demonstrate strong market performance, solidifying its position in the industry.